The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial.

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

A new drug by pharmaceutical giant Eli Lilly rivaling Ozempic and Wegovy could lead to 'significantly' more weight loss after ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...